Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are known for lipid reduction.
• Emerging evidence suggests PCSK9 inhibitors possess non-lipid-related pleiotropic effects.
• The impact on hemostasis in isolated hypercholesterolemia requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of PCSK9 inhibitors as monotherapy.
• To assess the impact on hemostatic markers in patients with isolated hypercholesterolemia.
• To explore potential non-lipid-related benefits of PCSK9 inhibition.

Main Methods:

• A trial involving 21 patients with isolated hypercholesterolemia and atherosclerosis.
• Alirocumab administration at 150 mg every two weeks for 90 days.
• Measurement of plasma lipids, glucose homeostasis factors, and hemostatic markers at baseline and post-treatment.

Main Results:

• Significant reduction in plasma fibrinogen, factor VII, and plasminogen activator inhibitor-1 (PAI-1) levels.
• No significant reduction in von Willebrand factor levels observed.
• Tendency towards prolonged partial thromboplastin and prothrombin times, indicating altered coagulation dynamics.

Conclusions:

• PCSK9 inhibitors demonstrate a multipotential effect on fibrinolysis and coagulation.
• These findings suggest potential future benefits for statin-intolerant or contraindicated patients.
• PCSK9 inhibition may offer therapeutic advantages beyond lipid lowering in specific patient populations.